Virax Biolabs to Present at 19th World Immune Regulation Meeting
Virax Biolabs (Nasdaq: VRAX) has announced its participation in the prestigious 19th World Immune Regulation Meeting (WIRM) taking place March 12-15, 2025, in Davos, Switzerland. The company's Chief Operating Officer, Dr. Nigel McCracken, will deliver a presentation titled 'Evaluation of T cell dysfunction in post acute infection syndromes' on March 12, 2025, at 20:00 in Foyer A1 of The Congress Center.
The biotechnology company, focused on viral disease diagnosis and immune response detection, will also showcase its immune profiling products at Booth 116. Management will be available to engage with research organizations and potential customers during the event.
WIRM 2025 is set to bring together approximately 600 scientists and clinicians worldwide, featuring scientific lectures, networking opportunities, and a poster exhibition in Davos.
Virax Biolabs (Nasdaq: VRAX) ha annunciato la sua partecipazione al prestigioso 19掳 Congresso Mondiale sulla Regolazione Immunitaria (WIRM), che si terr脿 dal 12 al 15 marzo 2025 a Davos, Svizzera. Il Chief Operating Officer dell'azienda, Dr. Nigel McCracken, presenter脿 un intervento intitolato 'Valutazione della disfunzione delle cellule T nei sindromi post-infezione acuta' il 12 marzo 2025 alle 20:00 nel Foyer A1 del Centro Congressi.
La societ脿 biotecnologica, focalizzata sulla diagnosi delle malattie virali e sulla rilevazione della risposta immunitaria, presenter脿 anche i suoi prodotti di profilazione immunitaria allo Stand 116. La direzione sar脿 disponibile per interagire con organizzazioni di ricerca e potenziali clienti durante l'evento.
Il WIRM 2025 riunir脿 circa 600 scienziati e clinici provenienti da tutto il mondo, offrendo conferenze scientifiche, opportunit脿 di networking e una mostra di poster a Davos.
Virax Biolabs (Nasdaq: VRAX) ha anunciado su participaci贸n en el prestigioso 19掳 Encuentro Mundial sobre Regulaci贸n Inmunitaria (WIRM), que se llevar谩 a cabo del 12 al 15 de marzo de 2025 en Davos, Suiza. El Director de Operaciones de la compa帽铆a, Dr. Nigel McCracken, presentar谩 una conferencia titulada 'Evaluaci贸n de la disfunci贸n de c茅lulas T en s铆ndromes post-infecci贸n aguda' el 12 de marzo de 2025 a las 20:00 en el Foyer A1 del Centro de Congresos.
La empresa biotecnol贸gica, centrada en el diagn贸stico de enfermedades virales y la detecci贸n de la respuesta inmune, tambi茅n exhibir谩 sus productos de perfilado inmune en el Stand 116. La direcci贸n estar谩 disponible para interactuar con organizaciones de investigaci贸n y clientes potenciales durante el evento.
El WIRM 2025 reunir谩 a aproximadamente 600 cient铆ficos y cl铆nicos de todo el mundo, presentando conferencias cient铆ficas, oportunidades de networking y una exposici贸n de p贸sters en Davos.
Virax Biolabs (Nasdaq: VRAX)電� 2025雲� 3鞗� 12鞚茧秬韯� 15鞚缄箤歆� 鞀れ渼鞀� 雼る炒鞀れ棎靹� 鞐措Μ電� 甓岇渼 鞛堧姅 鞝�19須� 靹戈硠 氅挫棴 臁办爤 須岇潣(WIRM)鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� COO鞚� Dr. Nigel McCracken鞚� 2025雲� 3鞗� 12鞚� 20:00鞐� 旎菠靺� 靹柬劙 Foyer A1鞐愳劀 '旮夓劚 臧愳椉 歃濏泟甑� 頉� T 靹疙彫 旮半姤 鞛レ暊 韽夑皜'霛茧姅 鞝滊鞚� 氚滍憸毳� 頃� 鞓堨爼鞛呺媹雼�.
氚旍澊鞓ろ厡韥� 須岇偓鞚� Virax Biolabs電� 氚旍澊霟姢 歆堧硲 歆勲嫧 氚� 氅挫棴 氚橃潙 瓴�於滌棎 欷戩爯鞚� 霊愱碃 鞛堨溂氅�, 攵�鞀� 116鞐愳劀 氅挫棴 頂勲韺岇澕毵� 鞝滍拡霃� 靹犽炒鞚� 鞓堨爼鞛呺媹雼�. 瓴届榿歆勳潃 頄夓偓 旮瓣皠 霃欖晥 鞐瓣惮 旮瓣磤 氚� 鞛犾灛 瓿犼皾瓿� 靻岉喌頃� 靾� 鞛堧弰搿� 頃� 瓴冹瀰雼堧嫟.
WIRM 2025電� 鞝� 靹戈硠鞐愳劀 鞎� 600氇呾潣 瓿柬暀鞛� 氚� 鞛勳儊鞚橁皜 氇澊電� 頄夓偓搿�, 雼る炒鞀れ棎靹� 瓿柬暀 臧曥棸, 雱ろ姼鞗岉偣 旮绊殞 氚� 韽姢韯� 鞝勳嫓臧� 歆勴枆霅� 鞓堨爼鞛呺媹雼�.
Virax Biolabs (Nasdaq: VRAX) a annonc茅 sa participation au prestigieux 19猫me Congr猫s Mondial sur la R茅gulation Immunitaire (WIRM), qui se d茅roulera du 12 au 15 mars 2025 脿 Davos, en Suisse. Le Directeur des op茅rations de l'entreprise, Dr. Nigel McCracken, pr茅sentera une conf茅rence intitul茅e '脡valuation de la dysfonction des cellules T dans les syndromes post-infection aigu毛' le 12 mars 2025 脿 20h00 dans le Foyer A1 du Centre des Congr猫s.
L'entreprise biotechnologique, ax茅e sur le diagnostic des maladies virales et la d茅tection de la r茅ponse immunitaire, pr茅sentera 茅galement ses produits de profilage immunitaire au Stand 116. La direction sera disponible pour interagir avec des organisations de recherche et des clients potentiels durant l'茅v茅nement.
Le WIRM 2025 rassemblera environ 600 scientifiques et cliniciens du monde entier, avec des conf茅rences scientifiques, des opportunit茅s de r茅seautage et une exposition de posters 脿 Davos.
Virax Biolabs (Nasdaq: VRAX) hat seine Teilnahme an dem prestigetr盲chtigen 19. Weltmeeting zur Immunregulation (WIRM) angek眉ndigt, das vom 12. bis 15. M盲rz 2025 in Davos, Schweiz, stattfinden wird. Der Chief Operating Officer des Unternehmens, Dr. Nigel McCracken, wird am 12. M盲rz 2025 um 20:00 Uhr im Foyer A1 des Kongresszentrums einen Vortrag mit dem Titel 'Bewertung der T-Zell-Dysfunktion bei postakuten Infektionssyndromen' halten.
Das Biotechnologieunternehmen, das sich auf die Diagnose von Viruskrankheiten und die Erkennung der Immunantwort spezialisiert hat, wird auch seine Produkte zur Immunprofilierung am Stand 116 pr盲sentieren. Das Management wird w盲hrend der Veranstaltung zur Verf眉gung stehen, um mit Forschungsorganisationen und potenziellen Kunden in Kontakt zu treten.
WIRM 2025 wird voraussichtlich etwa 600 Wissenschaftler und Kliniker aus der ganzen Welt zusammenbringen und wissenschaftliche Vortr盲ge, Networking-M枚glichkeiten und eine Poster-Ausstellung in Davos bieten.
- None.
- None.
Presentation Details:
Title: Evaluation of T cell dysfunction in post acute infection syndromes
Presenter:听Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs
Date:听Wednesday, March 12, 2025, at听20:00
Location:听Foyer A1, The Congress Center,听Davos,
Additionally, the Company will be showcasing its portfolio of immune profiling products for research use at Booth 116, and management will be available for discussions with research organizations and potential customers.
WIRM 2025 is an esteemed conference where approximately 600 scientists and clinicians from around the globe gather to discuss the latest advancements in immunology. This four-day event combines top-tier scientific lectures, informal networking, and a poster exhibition, all set against the stunning backdrop of
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit听.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
M: 303-482-6405
[email protected]听
View original content to download multimedia:
SOURCE Virax Biolabs
FAQ
When and where will Virax Biolabs (VRAX) present at WIRM 2025?
What will be the topic of Virax Biolabs' presentation at WIRM 2025?
Where can attendees find Virax Biolabs' product showcase at WIRM 2025?
How many participants are expected at WIRM 2025 where VRAX is presenting?
What products will Virax Biolabs (VRAX) showcase at WIRM 2025?
